We are live on
!
Find out more
Oric Pharmaceuticals
ORIC
ORIC
92 hedge funds and large institutions have $470M invested in Oric Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 20 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
117% more call options, than puts
Call options by funds: $4M | Put options by funds: $1.84M
80% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 20
62% more capital invested
Capital invested by funds: $291M → $470M (+$180M)
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
5.59% more ownership
Funds ownership: 88.12% → 93.71% (+5.6%)
2% more funds holding
Funds holding: 90 → 92 (+2)
Holders
92
Holders Change
+2
Holders Change %
+2.22%
% of All Funds
1.34%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.1%
New
20
Increased
36
Reduced
20
Closed
17
Calls
$4M
Puts
$1.84M
Net Calls
+$2.16M
Net Calls Change
+$2.23M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$28M |
| 2 |
Morgan Stanley
New York
|
+$6.05M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$4.77M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.39M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.77M |
Top Sellers
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$7.24M |
| 2 |
Millennium Management
New York
|
-$7.04M |
| 3 |
BlackRock
New York
|
-$4.61M |
| 4 |
O
OrbiMed
New York
|
-$2.68M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.43M |
